Pressmeddelanden från Oncoinvent

Bevaka pressreleaser

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Oncoinvent ASA: Grant of share options to the CEO 26 feb 07:00

Oncoinvent ASA: Second half 2025 results 17 feb 07:00

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026 16 feb 07:00

Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026 29 jan 07:00

Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial 08 jan 13:42

Oncoinvent ASA: Minutes from Extraordinary General Meeting 22 dec 2025 18:09

Oncoinvent ASA: Grant of share options – mandatory notification of trade 08 dec 2025 07:00

Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology 17 nov 2025 06:30

Oncoinvent ASA: Commencement of the subscription period for the Rights Issue 14 nov 2025 10:56

Oncoinvent ASA – Receipt of subscription rights in the rights issue by primary insiders and their close associates 03 nov 2025 12:55

Reminder: Invitation to presentation of Q3 2025 company update on November 4[th], 2025 03 nov 2025 08:55

Mandatory notification of trade 31 okt 2025 08:30

Oncoinvent appoints Dr. Ramzi Amri as new CFO 29 okt 2025 17:38

Merger of BerGenBio and Oncoinvent completed 29 okt 2025 15:16

Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies 24 okt 2025 07:59

BerGenBio and Oncoinvent – Key Dates for Completion of Merger 08 okt 2025 07:00

Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer 17 sep 2025 08:56

Oncoinvent ASA: Updated information regarding the contemplated Rights Issue and Merger 17 sep 2025 08:55

Oncoinvent ASA: Updated Key Information related to the contemplated Rights Issue 29 aug 2025 07:00

Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement 27 aug 2025 07:00

Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer 04 aug 2025 13:53

Oncoinvent shareholders approve the merger plan with BerGenBio 03 jul 2025 15:45

Oncoinvent ASA: Notice of Extraordinary General Meeting 30 jun 2025 22:11

Announcement of fully underwritten rights issue 30 jun 2025 22:01

BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue